10/584,632

=> d ibib abs hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2007:1258734 CAPLUS

DOCUMENT NUMBER:

147:541866
Preparation of trisubstituted 1H-pyrazoles as

inhibitors of transforming growth factor β

INVENTOR(S):

Li, Song; Li, Xingzhou; Dai, Xianping; Zheng, Zhibing;

Wang, Lili; Xiao, Junhai; Liu, Hongying

PATENT ASSIGNEE(S):

Institute of Pharmacology and Toxicology, Academy of

Military Medical Sciences, The Chinese People's

Liberation Army, Peop. Rep. China

SOURCE:

Faming Zhuanli Shenqing Gongkai Shuomingshu, 113pp.

II

CODEN: CNXXEV

DOCUMENT TYPE:

Patent


LANGUAGE:

Chinese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101062916	Α.	20071031	CN 2006-10078014	20060429
PRIORITY APPLN. INFO.:			CN 2006-10078014	20060429



The title trisubstituted 1H-pyrazole compds. I [wherein R1 and R2 = independently (un) substituted or (un) fused aryl or heterocyclyl; R3 = (un) substituted aryl, heterocyclyl, halo, alkyl, etc.], or isomers, pharmaceutically acceptable salts, or hydrates there of were prepared as inhibitors of transforming growth factor β (TGF- β). For example, II was prepared in a multi-step synthesis. II showed 45.28% inhibitory activity against TGF- β . The compds. are useful for treatment of chronic nephritis, arthritis, diabetic nephrosis, arteriosclerosis, pulmonary fibrosis, liver fibrosis, etc. (no data). IT 957654-40-9P 957654-45-4P 957654-50-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of trisubstituted 1H-pyrazoles as TGF- β inhibitors)

RN 957654-40-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(4-fluorophenyl)-N-(phenylmethyl)-1-(2pyridinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ N & & & \\ & & & \\ Ph-CH_2-NH-C & \\ & & & \\ & & & \\ O & & \\ \end{array}$$

RN 957654-45-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(4-fluorophenyl)-N-(2-furanylmethyl)-1-(2-pyridinyl)- (CA INDEX NAME)

RN 957654-50-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(4-fluorophenyl)-1-(2-pyridinyl)-N-(3-pyridinylmethyl)- (CA INDEX NAME)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:14431 CAPLUS

DOCUMENT NUMBER: 146:121962

TITLE: Pyrazole based LXR modulators and their preparation,

pharmaceutical compositions and use in the treatment

of diseases

INVENTOR(S):
Busch, Breet B.; Flatt, Brenton T.; Gu, Xiao Hui;

Martin, Richard; Mohan, Raju; Nyman, Michael Charles; Schweiger, Edwin; Stevens, William C., Jr.; Wang, Tie

Lin; Xie, Yinong

PATENT ASSIGNEE(S):

Exelixis, Inc., USA

SOURCE:

GI

PCT Int. Appl., 533pp., which

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATE	PATENT NO.					KIND DATE					APPLICATION NO.					DATE		
-						-				 -					-			
WO 2	0070	0255	59		A1		2007	0104	1	WO 2	006-1	US24	749		2	0060	626	
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	ΚP,	
		KR,	ΚZ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	
		MW,	MX,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	ŔS,	RU,	
		SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	
		US,	UZ,	VC,	VN,	ZA,	ZM,	ZW										
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ĖЈ,	
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,	
		GM,	KE,	LS,	MW,	MZ,	NΑ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	AZ,	BY,	
		KG,	ΚZ,	MD,	RU,	ТJ,	TM											
PRIORITY	APPL	N. I	NFO.	. :					1	US 20	005-	6943	72P		P 20	0050	627	
									Ţ	US 20	005-	7361:	20P	:	P 2	0051	110	
OTHER SOURCE(S):					MARPAT 146:121962													

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Compds. of the invention, such as compds. of formulas I, II, III, and IV AR and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed. Compds. of formulas I - IV wherein R1 is (un) substituted (hetero) aryl, (un) substituted alkyl, (un) substituted alkenyl, (un) substituted (thio) ethers, etc.; R2 and R21 are independently (un) substituted alkyl, (un) substituted alkenyl, (un) substituted alkyldiyl, H, halo, NO2, CN, (hetero)aryl, etc.; R3 is(un)substituted alkyl, (un) substituted alkyldiyl, (un) substituted alkenyl, (un) substituted acetyl, (un) substituted thioacetyl, etc.; G is (un) substituted (hetero)aryl, (un)substituted biaryl, (un)substituted alkenoyl, etc.; and their pharmaceutically acceptable salts, isomers, and prodrugs thereof, are claimed. Example compound V was prepared by acylation of 2-acetyl-5-bromothiophene with Et trifluoroacetate; the resulting 1-(5-bromothien-2-yl)-4,4,4-trifluorobutane-1,3-dione underwent cyclization with 2,5-dichlorophenylhydrazine hydrochloride to give 5-(5-bromothien-2-yl)-1-(2,5-dichlorophenyl)-3-trifluoromethyl-1Hpyrazole, which underwent Suzuki cross-coupling with 3aminosulfonylphenylboronic acid to give compound II. All the invention compds. were evaluated for their LXR modulatory activity. From the assay, it was determined that several of the tested compds. exhibited IC50 values of < 1 μΜ.

IT 918319-15-0P 918319-16-1P 918322-06-2P 918322-07-3P 918325-77-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazoles as LXR modulators and their use in the treatment of diseases)

pyridinyl]-(CA INDEX NAME)

$$F_3C \longrightarrow C1 \longrightarrow C1 \longrightarrow S \longrightarrow Me$$

$$F_3C \longrightarrow CH_2 \longrightarrow NH \longrightarrow C \longrightarrow C1 \longrightarrow S \longrightarrow Me$$

918325-77-6 CAPLUS RN

1H-Pyrazole-3-carboxamide, 5-[3-chloro-3'-(methylsulfonyl)[1,1'-biphenyl]-CN 4-yl]-N-(2-methylpropyl)-1-[2-(trifluoromethyl)-3-pyridinyl]- (CA INDEX NAME)

REFERENCE COUNT:

12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2006:325402 CAPLUS

DOCUMENT NUMBER:

145:103666

TITLE:

Preparation of pyrazoles as cyclooxygenase inhibitors

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE:

Aust. Pat. Appl., 68 pp.

DOCUMENT TYPE:

CODEN: AUXXCM Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
AU 2004200420	A1	20040930	AU 2004-200420		20040206
PRIORITY APPLN. INFO.:			AU 2003-901100	Α	20030311
OTHER SOURCE(S):	MARPAT	145:103666			
GI					

ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

2005:612279 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 143:133365

Preparation of pyrazole carboxamide derivatives as TITLE:

platelet aggregation inhibitors for treatment of

ischemia

INVENTOR(S):

Kanaya, Naoaki; Ishiyama, Takashi; Muto, Ryo; Ochiai, Yuichi; Watanabe, Toshiyuki; Kuru, Noriko Daiichi Pharmaceutical Co., Ltd., Japan

PCT Int. Appl., 329 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT ASSIGNEE(S):

						KIND DATE 									DATE			
1	wo	2005	0637:								WO 2	004-	JP19	582		2	0041	227
		W:						AU,										
								DE,		-	-	•						
			GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	KZ,	LC,
				•	•	•		LV,	•			•	-	-	-	-	-	
			NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	NΑ,	SD,	SL,	SZ,	TZ,	ŬĠ,	ZM,	ZW,	AM,
			ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
			EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,
			RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,
			MR,	ΝE,	SN,	TD,	TG											
	ΑU	20043	3092	54		A1		2005	0714		AU 2	004-	3092	54		2	0041	227
(CA	25516	604			A1		2005	0714	1	CA 2	004-	2551	604		2	0041	227
	EΡ	16986	626			A1		2006	0906		EP 2	004-	8079	37		2	0041	227
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	FI,	RO,	CY,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,	IS		
(CN	1902	191			Α		2007	0124		CN 2	004-	8003	9042		2	0041	227
]	MΧ	20061	PA07	424		Α		2006	0913	1	MX 2	006-	PA74	24		2	0060	626
1	US	20072	2192	10							US 2	007-	5846	32		2	0070	227
PRIOR	ITY	APP							i	JP 2	003-	4347	26	1				
							JP 2004-12154 A 20040120						120					
								JP 2004-321117 A 20041104										
									1	WO 2	004-	JP19	582	7	W 2	0041	227	
]] 1	CN 1902191 MX 2006PA07424 NO 2006003090 US 2007219210 PRIORITY APPLN. INFO.:					A A		2006 2006	0913 0921	1	MX 2 NO 2 US 2 JP 2 JP 2 JP 2	006-: 006-: 007-: 003-: 004-:	-80039042 -PA7424 -3090 -584632 -434726 -12154		1 1 1	2 2 A 2 A 2 A 2	0060 0060 0070 0031 0040	626 704 227 226 120 104

OTHER SOURCE(S): MARPAT 143:133365

GI

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1124567 CAPLUS

DOCUMENT NUMBER: 142:74572

TITLE: Preparation of heterocyclic compounds for treating

hepatitis C virus

INVENTOR(S): Vourloumis, Dionisios; Takahashi, Masayuki; Winters,

Geoff; Zhou, Jinglan; Duchene, Russell

PATENT ASSIGNEE(S): Anadys Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 416 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.				KIND DATE			APPLICATION NO.									
						-									-		
WO	2004	1103	51		A2		2004	1223	,	WO 2	004-1	JS15:	249		2	0040	514
WO	2004	1103	51		A3		2005	0428									
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	ŪG,	US,	UΖ,	VC,	VN,	ÝŪ,	ZA,	ZM,	zw
	RW:	BW,	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,
		ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,
		SN,	TD,	TG													
US	2005	0753	75		Al		2005	0407	•	US 2	004-	8455	87		2	0040	514
PRIORITY APPLN. INFO.:			US 2003-470200P P 2003						0030	514							
OTHER S	OTHER SOURCE(S):				MARPAT 142:74572												
GI ·	• •																

AB The title compds. I [X, Y, Z = C, N; W = N, O, S; R1, R3-R5 = H, halo, NO2, etc.; R2 = H, alkyl], useful for treating Hepatitis C virus, were prepared E.g., a multi-step synthesis of II, starting from 2'-hydroxy-5'-methoxyacetophenone, was given. The compds. I were tested for inhibition of HCV replication in in vitro assays (the results of EC50 assay are given for 640 compds. I). The pharmaceutical composition comprising the compound I is disclosed.

IT 814262-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

RN 814262-81-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(4-methoxyphenyl)-N-propyl-1-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:796496 CAPLUS

DOCUMENT NUMBER: 141:290547

TITLE: Fungicidal compositions comprising

N-phenyl-N-[4-(4-pyridyl)-2-pyrimidin-2-yl]amine

derivatives

INVENTOR(S): Ackerman, Peter; Stierli, Daniel; Jung, Pierre Marcel

Joseph; Maienfisch, Peter; Cederbaum, Fredrik Emil

Malcolm; Wenger, Jean-Frederic

PATENT ASSIGNEE(S): Syngenta Participations AG, Switz.

Patent

SOURCE: Brit. UK Pat. Appl., 112 pp.

CODEN: BAXXDU

DOCUMENT TYPE:

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

GΙ

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2399754	A	20040929	GB 2004-3967	20040223
PRIORITY APPLN. INFO.:			GB 2003-7269 A	20030328
OTHER SOURCE(S):	MARPAT	141:290547		

Ι

Compns. for protecting plants, especially fungicidal compns., comprise AB N-phenyl-N-[4-(4-pyridyl)-2-pyrimidin-2-yl]amine derivs. (I, R1 = halo or (un) substituted alkyl, alkoxy, alkenyloxy, alkynyloxy, thioalkyl, aryl, etc.; R2-R9 = H, (un) substituted alkyl, aryl, etc.; R10 = H, (un) substituted alkyl, alkenyl, etc.; R11 = H, C1-4 alkyl, C3-4 alkenyl, etc.; m = 0, 1, 2, or 3; n, p = 0 or 1; q = 1 or 2) or a salt thereof, together with a suitable carrier and optionally addnl. active compds. Thus, spraying 1-wk-old wheat plants 0.02% I (in a test with 7 such compds.) resulted in >70% control of fungal infection assessed 10 days after inoculation with Puccinia graminis.

764698-93-3 IT

> RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)

(as fungicide for plant protection)

764698-93-3 CAPLUS RN

1H-Pyrazole-3-carboxamide, 1-[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-CN 2-pyridinyl]-5-(2,4-difluorophenyl)-N-methyl- (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2008 ACS on STN T.4 ANSWER 7 OF 10

ACCESSION NUMBER: 2004:493684 CAPLUS

DOCUMENT NUMBER: 141:54327

Preparation of pyrazole derivatives useful as COX-1 TITLE:

inhibitors

INVENTOR(S): Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko;

Okumura, Kazuo; Nakamura, Katsuya

Fujisawa Pharmaceutical Co., Ltd., Japan PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 436 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT	NO.			KIN	D	DATE		j	APPL	ICAT:	ION I	NO.		DATE			
					-									-			
WO 2004	0506	32		A1		2004	0617	1	WO 2	003-	JP14	489		2	0031	114	
₩:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	ΒA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DΖ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KR,	ΚZ,	LC,	LK,	LR,	LS,	
	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NΙ,	NO,	NZ,	OM,	PG,	
	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	TM,	TN,	TR,	
	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	ΥU,	ZA,	ZM,	zw					
RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	
	BY,	KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	

```
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                20040617
                                             CA 2003-2505945
                                                                    20031114
    CA 2505945
                          A1
    AU 2003302635
                          Al
                                20040623
                                             AU 2003-302635
                                                                     20031114
    EP 1567503
                          Αl
                                20050831
                                             EP 2003-812289
                                                                     20031114
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                             BR 2003-16332
                                                                     20031114
    BR 2003016332
                          Α
                                20050927
                                             CN 2003-80104548
                                                                     20031114
    CN 1717393
                          Α
                                20060104
                          Т
                                             JP 2004-570721
    JP 2006514095
                                                                     20031114
                                20060427
    MX 2005PA05742
                                             MX 2005-PA5742
                                                                     20050530
                          Α
                                20050816
    IN 2005CN01453
                          Α
                                20070622
                                             IN 2005-CN1453
                                                                     20050629
                          Α
                                             NO 2005-3215
                                                                    20050630
    NO 2005003215
                                20050901
PRIORITY APPLN. INFO.:
                                             AU 2002-953019
                                                                 A 20021202
                                             AU 2002-953602
                                                                 A 20021230
                                             AU 2003-902015
                                                                    20030429
                                                                 Α
                                             WO 2003-JP14489
                                                                 W 20031114
```

OTHER SOURCE(S):

MARPAT 141:54327

GΙ

$$R^4-Z-X$$
 N
 R^2
 R^3
 Y
 R^2

AB The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc.; R4 = H, CN, OH, etc.; X = 0, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.

RN 705934-64-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-1-(6-methoxy-3-pyridinyl)-N-methyl-5-[4-[2-[(methylsulfonyl)oxy]ethyl]phenyl]- (CA INDEX NAME)

CN 1H-Pyrazole-3-carboxamide, N-methoxy-1-(6-methoxy-3-pyridinyl)-N-methyl-5-[4-[2-[(methylsulfonyl)oxy]ethyl]phenyl]- (CA INDEX NAME)

RN 705939-37-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[4-(2-aminoethyl)phenyl]-N-methoxy-1-(6-methoxy-3-pyridinyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} \\ \\ \text{N} \\ \\ \text{N} \\ \\ \text{Me} - \text{N} - \text{C} \\ \\ \\ \text{MeO} \quad \text{O} \\ \end{array}$$

•x HCl

REFERENCE COUNT:

5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2004:493568 CAPLUS

DOCUMENT NUMBER:

141:54325

TITLE:

Preparation of pyrazole derivatives useful as COX-1

inhibitors

INVENTOR(S):

Shirai, Fumiyuki; Azami, Hidenori; Kayakiri, Natsuko;

Okumura, Kazuo; Nakamura, Katsuya

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: U.S. Pat. Appl. Publ., 142 pp. CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004116475	A1	20040617	US 2003-706999	20031114
US 7183306	B2	20070227	•	
CN 1717393	Α	20060104	CN 2003-80104548	20031114
US 2007112037	A1	20070517	US 2006-610230	20061213
PRIORITY APPLN. INFO.:			AU 2002-953019 A	20021202
			AU 2002-953602 A	20021230
			AU 2003-902015 A	20030429
			US 2003-706999 A	3 20031114
OTHER SOURCE(S):	MARPAT	141:54325		

$$R^4-Z-X$$
 N
 N
 R^2
 R^3
 Y

The compds. [I; R1 = H, alkyl; R2 = alkyl, haloalkyl, hydroxyalkyl, etc.; R3 = alkoxy, halo, CN, etc.; R4 = H, CN, OH, etc.; X = 0, S, SO, SO2; Y = CH, N; Z = alkylene, alkenylene; m = 0-1], were prepared E.g., a 3-step synthesis of 4-[3-isopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenol, was given. The compds. I have an inhibiting activity against COX, particularly a selective inhibiting activity against COX-1 (data for representative compds. I is given). The pharmaceutical composition comprising the compound I is claimed.

I

CN 1H-Pyrazole-3-carboxamide, N-ethyl-1-(6-methoxy-3-pyridinyl)-N-methyl-5-[4-[2-[(methylsulfonyl)oxy]ethyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & & & & \\ & N & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ &$$

705939-37-3 CAPLUS RN

1H-Pyrazole-3-carboxamide, 5-[4-(2-aminoethyl)phenyl]-N-methoxy-1-(6-CN methoxy-3-pyridinyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} \\ \\ N \\ \\ N \\ \\ \text{CH}_2-\text{CH}_2-\text{NH}_2 \\ \\ \text{Me}-\text{N}-\text{C} \\ \\ | & | \\ \\ \text{MeO} & \text{O} \\ \end{array}$$

HCl

REFERENCE COUNT:

35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

T.4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2003:442769 CAPLUS

DOCUMENT NUMBER:

TITLE:

139:190635

Discovery of a potent and selective series of pyrazole

bacterial methionyl-tRNA synthetase inhibitors

AUTHOR (S):

SOURCE:

Finn, John; Mattia, Karen; Morytko, Mike; Ram, Siya; Yang, Yingfei; Wu, Ximao; Mak, Elsa; Gallant, Paul;

Keith, Dennis

CORPORATE SOURCE:

Cubist Pharmaceutical Inc., Lexington, MA, 02421, USA

Bioorganic & Medicinal Chemistry Letters (2003),

13(13), 2231-2234

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER:

DOCUMENT TYPE:

Elsevier Science B.V.

Journal

LANGUAGE:

English

OTHER SOURCE(S): CASREACT 139:190635

Starting with a micromolar lead identified from high-throughput screening,

a series of pyrazoles were discovered with significantly improved potency on bacterial methionyl-tRNA synthetase and selectivity over human methionyl-tRNA synthetase.

IT 583850-56-0P 583850-57-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(potent and selective pyrazole inhibitors of bacterial methionyl-tRNA synthetase in comparison with human enzyme)

RN 583850-56-0 CAPLUS

CN Glycine, N-[[5-(2',4'-dichloro[1,1'-biphenyl]-4-yl)-1-(3-pyridinyl)-1H-pyrazol-3-yl]carbonyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 583850-57-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(2',4'-dichloro[1,1'-biphenyl]-4-yl)-1-(3-pyridinyl)-N-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

1992:612965 CAPLUS

DOCUMENT NUMBER:

117:212965

TITLE:

Preparation of N-(pyrazolylcarbonyl)amino acids and

analogs as antipsychotics

INVENTOR (S):

Boigegrain, Danielle; Gully, Robert; Jeanjean,

Francis; Molimard, Jean Charles

PATENT ASSIGNEE(S):

Sanofi SA, Fr.

SOURCE:

Fr. Demande, 53 pp.

CODEN: FRXXBL

DOCUMENT TYPE:

LANGUAGE:

Patent French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2665898	A1	19920221	FR 1990-10486	19900820
FR 2665898	B1	19940311		
HU 59106	A2	19920428	HU 1991-2750	19910817
HU 217435	В	20000128	110 1331 1750	13310017
FI 9103917	A	19920221	FI 1991-3917	19910819
FI 104170	В	19991130	11 1991 3317	19910019
FI 104170	B1	19991130		
NO 9103234	A	19920221	NO 1991-3234	19910819
NO 3103234 NO 300212	B1	19970428	110 1991-3234	17710017
BR 9103550	A	19920407	BR 1991-3550	19910819
IL 99225	A	19951031	IL 1991-99225	19910819
PL 169085	B1	19960531	PL 1991-291463	19910819
RU 2066317	C1	19960910	RU 1991-5001452	19910819
CA 2049514	A1	19920221	CA 1991-2049514	
CA 2049514 CA 2049514	C	19920221	CA 1991-2049514	19910820
			7H 1001 02F06	10010000
AU 9182596	A	19920227	AU 1991-82596	19910820
AU 646683	B2	19940303	ED 1001 400060	10010000
EP 477049	A1	19920325	EP 1991-402269	19910820
EP 477049	B1	19991201	ID OD IT III	NI CE
			GB, GR, IT, LI, LU,	
ZA 9106583	A	19920527	ZA 1991-6583	19910820
JP 04244065	A	19920901	JP 1991-208108	19910820
CZ 281864	B6	19970312	CZ 1991-2574	19910820
CA 2166903	C	19980901	CA 1991-2166903	19910820
CA 2166902	C	19990119	CA 1991-2166902	19910820
CA 2166901	C	19990126	CA 1991-2166901	19910820
KR 223074	B1	19991015	KR 1991-14358	19910820
AT 187167	T	19991215	AT 1991-402269	19910820
ES 2142798	Т3	20000501	ES 1991-402269	19910820
LV 10434	В	19951020	LV 1993-138	19930225
LT 3520	В	19951127	LT 1993-656	19930615
US 5420141	Α	19950530	US 1993-119830	19930913
US 5635526	A	19970603	US 1995-393829	19950224
US 5607958	A	19970304	US 1995-394757	19950227
US 5616592	A	19970401	US 1995-394756	19950227
US 5744493	A	19980428	US 1996-775150	19961231
US 5744491	A	19980428	US 1997-778105	19970102
HK 1005136	A1	20000922	HK 1998-104340	19980519
GR 3032732	Т3	20000630	GR 2000-400431	20000223
PRIORITY APPLN. INFO.:			FR 1990-10486	A 19900820
			CA 1991-2049514	A3 19910820
			US 1991-747359	B1 19910820
			US 1993-119830	A3 19930913
			US 1995-393829	A3 19950224
			US 1995-394756	A3 19950227.
OTHER SOURCE(S):	MARPAT	117:212965	•	

OTHER SOURCE(S):

MARPAT 117:212965

GI

$$Q^{1} = \begin{array}{c} R^{5} & R^{4} \\ R^{1}N & Q^{2} = \\ R^{2} & N \\ R^{2} & R^{2} \end{array}$$

AB R3CONR(CH2)nCXX1COZ [R = H, alkyl; R3 = pyrazolyl group Q1 or Q2; R1 = (substituted) Ph, carboxyalkyl, alkoxycarbonylalkyl, pyridyl, etc.; R2 = (substituted) PhCH2; R4 = H, halo, alkyl; R5 = alkyl, (substituted) Ph, naphthyl, pyridyl, etc.; R4R5 = atoms to complete a benznellated ring; X = H, alkyl; X1 = H, (substituted) alkyl, (hetero)aralkyl, etc.; when n = 0, RX1 = (hydroxy substituted) (CH2)4-6; CXX1 = cycloalkylidene; Z = OH, NH2, alkoxy, etc.; n = 0-3] were prepared as neurotensin receptor ligands (no data). Thus, R3CO2H (R3 = Q1; R1 = Ph, R4 = H, R5 = 4-pyridyl) was condensed with L-leucine Me ester in the presence of Et3N and R6OP(NMe2)3PF6 (R6 = benzotriazol-1-yl) to give title compound I.

RN 144251-99-0 CAPLUS

CN L-Phenylalanine, N-[[5-(4-methylphenyl)-1-(2-pyridinyl)-1H-pyrazol-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 144252-00-6 CAPLUS

CN L-Phenylalanine, N-[[5-(4-methylphenyl)-1-(2-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

=> d his

(FILE 'HOME' ENTERED AT 08:24:19 ON 31 JAN 2008)

FILE 'REGISTRY' ENTERED AT 08:24:37 ON 31 JAN 2008

L1 STRUCTURE UPLOADED

L2 . 4 S L1

L3 236 S L1 FULL

FILE 'CAPLUS' ENTERED AT 08:25:07 ON 31 JAN 2008

L4 10 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR

G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

STM-Structure Seasel 1131/08

=> d ibib abs hitstr 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2007:565055 CAPLUS

DOCUMENT NUMBER:

147:9900

TITLE:

Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid

modulators and their preparation, pharmaceutical

compositions and use in the treatment of diseases

Xia, Mingde; Liotta, Fina; Pan, Meng; Wachter, Michael

P.; Lu, Huajun

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl. Publ., 39pp.

CODEN: USXXCO

DOCUMENT TYPE:

INVENTOR(S):

Patent

LANGUAGE:

GI

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE		DATE
US 2007117858	A1 200705	324 US 2006-560431	20061116
WO 2007061948	A2 200705	31 WO 2006-US44890	20061117
WO 2007061948	A3 200707	'12	
W: AE, AG, AL	. AM. AT. AU. A	AZ, BA, BB, BG, BR, BW,	BY, BZ, CA, CH,
•		OK, DM, DZ, EC, EE, EG,	
		IU, ID, IL, IN, IS, JP,	
		R, LS, LT, LU, LV, LY,	
MN, MW, MX	, MY, MZ, NA, N	IG, NI, NO, NZ, OM, PG,	PH, PL, PT, RO,
RS, RU, SC	, SD, SE, SG, S	SK, SL, SM, SV, SY, TJ,	TM, TN, TR, TT,
TZ, UA, UG	, US, UZ, VC, V	N, ZA, ZM, ZW	
• •		DE, DK, EE, ES, FI, FR,	GB, GR, HU, IE,
		IL, PL, PT, RO, SE, SI,	
		GQ, GW, ML, MR, NE, SN,	
		SD, SL, SZ, TZ, UG, ZM,	
			2W, AM, AZ, DI,
KG, KZ, MD	, RU, TJ, TM, A	AP, EA, EP, OA	
PRIORITY APPLN. INFO.:		US 2005-739129P	P 20051123
OTHER SOURCE(S):	MARPAT 147:99	+00	

AB This invention is directed to a substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulator compound of formula I: or a form thereof, and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease. Compds. of formula I wherein X1

II

ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2007:14431 CAPLUS

DOCUMENT NUMBER:

146:121962

TITLE:

Pyrazole based LXR modulators and their preparation,

pharmaceutical compositions and use in the treatment

of diseases

INVENTOR(S):

Busch, Breet B.; Flatt, Brenton T.; Gu, Xiao Hui; Martin, Richard; Mohan, Raju; Nyman, Michael Charles;

Schweiger, Edwin; Stevens, William C., Jr.; Wang, Tie

Lin; Xie, Yinong

PATENT ASSIGNEE(S):

SOURCE:

GI

Exelixis, Inc., USA PCT Int. Appl., 533pp., which

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT I	NO.	KI	ND	DATE			APPL	ICAT:	I NOI	. 01		DATE			
												-			
WO 2007	002559	A	1	2007	0104	1	WO 2	006-1	JS24	749		2	0600	526	
. M:	AE, AG,	AL, AM	, AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
	CN, CO,	CR, CU	, CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
	GE, GH,	GM, HN	, HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	KΡ,	
	KR, KZ,	LA, LC	, LK,	LR,	LS,	LT,	LU,	LŲ,	LY,	MA,	MD,	MG,	MK,	MN,	
	MW, MX,	MZ, NA	, NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	RU,	
	SC, SD,	SE, SG	, SK,	SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	ŪĠ,	
	US, UZ,	VC, VN	, ZA,	ZM,	ZW										
RW:	AT, BE,	BG, CH	, CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
	IS, IT,	LT, LU	, LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
	CF, CG,	CI, CM	, GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,	
	GM, KE,	LS, MW	, MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
	KG, KZ,	MD, RU	, TJ,	TM											
PRIORITY APP	LN. INFO.	. : .				1	US 2	005-	5943°	72P		P 20	0050	527	
									US 2005-736120P				P 20051110		
OTHER SOURCE	THER SOURCE(S):				MARPAT 146:12196				L962						

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Compds. of the invention, such as compds. of formulas I, II, III, and IV AB and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed. Compds. of formulas I - IV wherein R1 is (un) substituted (hetero) aryl, (un) substituted alkyl, (un) substituted alkenyl, (un) substituted (thio) ethers, etc.; R2 and R21 are independently

918327-63-6 CAPLUS RN

1H-Pyrazole-3-carboxamide, 1-(2-chlorophenyl)-N-(2-hydroxy-1-methylethyl)-CN 5-[5-[3-(methylsulfonyl)phenyl]-2-thienyl]- (CA INDEX NAME)

RN918327-64-7 CAPLUS

1H-Pyrazole-3-carboxamide, 1-(2-chlorophenyl)-N-methyl-5-[5-[3-CN (methylsulfonyl)phenyl]-2-thienyl]-N-(3-pyridinylmethyl)- (CA INDEX NAME)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CAPLUS COPYRIGHT 2008 ACS on STN L4ANSWER 3 OF 11

ACCESSION NUMBER:

2006:1183159 CAPLUS

DOCUMENT NUMBER:

146:401872

TITLE:

A convenient access to functionalized pyrazole, pyrazolyl-azole, and pyrazolo[3,4-d]pyridazine

derivatives

AUTHOR (S):

Dawood, Kamal M.; Farag, Ahmad M.; Abdel-Aziz, Hatem

Α.

CORPORATE SOURCE:

Department of Chemistry, Faculty of Science, Cairo

University, Giza, 12613, Egypt

SOURCE:

Journal of the Chinese Chemical Society (Taipei,

Taiwan) (2006), 53(4), 873-880

CODEN: JCCTAC; ISSN: 0009-4536

PUBLISHER:

Chinese Chemical Society

DOCUMENT TYPE:

Journal

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006

2006:147271 CAPLUS

DOCUMENT NUMBER:

144:233068

TITLE:

Preparation of substituted pyrazoles as adenosine

receptor inhibitors

INVENTOR(S):

Bloomfield, Graham Charles; Leblanc, Catherine;

McCarthy, Clive; Press, Neil John

PATENT ASSIGNEE(S):

Novartis AG, Switz.; Novartis Pharma GmbH

SOURCE:

PCT Int. Appl., 30 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PAT				KIND DATE			;	APPI	JICAT:	ION I	NO.	DATE						
																-			
		2006							0216	1	WO 2	2005-1	EP86	96		2	0050	810	
	WO	2006	0158	60		А3		2006	0615										
		₩:	ΑE,	AG,	ΑL,	AM,	AΤ,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KM,	ΚP,	KR,	ΚZ,	
			LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NΑ,	
			NG,	NΙ,	NO,	ΝZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	
			SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	ŪG,	US,	UZ,	VC,	VN,	YU,	
			ZA,	ZM,	ZW														
		RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
			IS,	ΙT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
			CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝĒ,	SN,	TD,	TG,	BW,	GH,	
			GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑŻ,	BY,	
			KG,	ΚZ,	MD,	RU,	TJ,	TM											
•	ΑU	2005	2703	14		A1		2006	0216		AU 2	2005-2	2703	14		2	0050	810	
	CA	2572	752			A1		2006	0216	(CA 2	2005-2	2572	752		2	0050	810	
	ΕP	1799	206			A2		2007	0627]	EP 2	2005-	7775	27		. 2	0050	310	
		R:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
			IS,	IT,	LΙ,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR		
	CN	1010	0162	5		Α		2007	0718	(CN 2	2005-8	8002	6991		2	0050	310	
		20061															0061	229	
	KR	2007	0328	12		Α		2007	0322	3	KR 2	2007-	70324	49		2	0070	209	
		2007															0070	329	
PRIO	RITY	APP	LN.	INFO	. :					(GB 2	2004 - 3	1791	0	1	A .2	0040	811	
	THIORITI MITELL. THE O										WO 2005-EP8696					W 20050810			

OTHER SOURCE(S): MARPAT 144:233068

GI

876376-71-5 CAPLUS RN

1H-Pyrazole-3-carboxamide, 1-(3-chlorophenyl)-5-(4-pyridinyl)-N-(4-CN pyridinylmethyl) - (CA INDEX NAME)

876376-73-7 CAPLUS RN

1H-Pyrazole-3-carboxamide, 1-(3-chlorophenyl)-5-(4-pyridinyl)-N-(3-CN pyridinylmethyl) - (CA INDEX NAME)

ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN L4

ACCESSION NUMBER:

2005:1242633 CAPLUS

DOCUMENT NUMBER:

144:6785

TITLE:

Preparation of pyrazole derivatives having affinity

· for the cannabinoidergic CB1 and/or CB2 receptors

INVENTOR(S):

Lazzari, Paolo; Ruiu, Stefania; Pinna, Gerard Aime;

Murineddu, Gabriele

PATENT ASSIGNEE(S):

Italy

SOURCE:

U.S. Pat. Appl. Publ., 24 pp.

CODEN: USXXCO Patent

DOCUMENT TYPE:

English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PAT	PATENT NO.				KIND		DATE		1	APPLICATION NO.				DATE			
						-			-						-	- -	
US	2005	2612	81		Al		2005	1124	τ	JS :	2005-	1346	27		2	0050	523
CA	2507	712			A1		2005	1124	(CA 2	2005-	2507	712		2	0050	517
EP	1602	656			A1		2005	1207	I	EP 2	2005-	1083	1		2	0050	519
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR.	IT,	LI,	LU,	NL,	ŜΕ,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,
_		BA,	HR,	IS,	YU												
JP	2005	3504	58		Α		2005	1222	j	JP 2	2005-	1509	31		2	0050	524
PRIORITY	APF	LN.	INFO	. :						IT :	2004-1	MI10:	32	7	A 2	0040	524
OTHER SO	OURCE	(S):			CASI	REAC	T 14	4:678	35; N	(AR	PAT 1	44:6	785				

ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2005:612279 CAPLUS

DOCUMENT NUMBER:

143:133365

TITLE:

Preparation of pyrazole carboxamide derivatives as

platelet aggregation inhibitors for treatment of

INVENTOR(S):

Kanaya, Naoaki; Ishiyama, Takashi; Muto, Ryo; Ochiai, Yuichi; Watanabe, Toshiyuki; Kuru, Noriko Daiichi Pharmaceutical Co., Ltd., Japan

PCT Int. Appl., 329 pp.

PATENT ASSIGNEE(S): SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PA'	TENT I	NO.			KIN:										D.	ATE	
	WO	2005	 0637:	 37				2005				2004-				2	 0041.	 227
		W:	ΑE,	AG,	AL,	AM,	AT,	, AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	, ID,	IL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LC,
			LK,	LR,	LS,	LT,	LU	LV,	MA,	MD,	MG	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
								PL,										
			TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	KE,	LS	, MW,	MZ,	NA,	SD	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
			AZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
			EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,
								BF,										
			MR,	NE,	SN,	TD,	TG											
	AU	2004	3092	54		A1		2005	0714	٠.	AU 2	2004-	3092	54		2	0041	227
	CA	2551	604			A1		2005	0714		CA 2	2004~	2551	604		2	0041	227
	EP.	1698	626			A1		2006	0906		EP 2	2004-	8079	37		2	0041	227
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	FI,	RO,	CY,	TR,	BG,	CZ,	EE,	HU,	PL,	SK,	IS		
	CN	1902	191			A		2007	0124		CN 2	2004 -	8003	9042		2	0041	227
		2006				Α		2006	0913	1	MX 2	2006-	PA74	24		2	0060	626
	NO	20060	0030	90		Α		2006	0921		NO 2	2006-	3090			2	0060	704
	US	20072	2192	10		A1		2007	0920		US 2	2007-	5846	32		ż	0070	227
PRIO	RITY	APPI	LN.	INFO	. :					1	JP 2	2003 -	4347	26	7	A 2	0031	226
•										1	JP 2	2004 -	1215	4	1	A 2	0040	120
										1	JP 2	2004 -	3211	17	7	A 2	0041	104
										1	WO 2	2004 -	JP19	582	7	W 2	0041	227
OTHER	2 90	אוופרד	101.			MADI	ידעם	1/2.	1222	5								

OTHER SOURCE(S):

MARPAT 143:133365

GI

RN 858596-37-9 CAPLUS

CN 4-Morpholinecarboxamide, N-[[6-[3-[[(1,1-dimethylethyl)amino]carbonyl]-1-phenyl-1H-pyrazol-5-yl]-3-pyridinyl]methyl]- (CA INDEX NAME)

RN 858596-39-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1,1-dimethylethyl)-1-phenyl-5-[5-[[[[(tetrahydro-2H-pyran-4-yl)amino]carbonyl]amino]methyl]-2-pyridinyl]-(CA INDEX NAME)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:216816 CAPLUS

DOCUMENT NUMBER:

140:236100

TITLE:

Synthesis of sarcolysin oligopeptide derivatives for

use in the treatment of cancer

INVENTOR(S):

Boopathy, Dhanapal

PATENT ASSIGNEE(S):

Lipal Biochemicals A.-G. c/o University of Zurich,

Switz.

SOURCE:

Ger. Offen., 24 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent German

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND DATE	APPLICATION N	NO. DATE
DE 10239832	A1 200403	318 DE 2002-10239	9832 20020829
WO 2004024755	A2 20040	325 WO 2003-EP963	20030829
WO 2004024755	A3 20041	118	
W: AE, AG, AL,	AM, AT, AU, A	AZ, BA, BB, BG, BR,	BY, BZ, CA, CH, CN,
CO, CR, CU,	CZ, DE, DK, I	DM, DZ, EC, EE, ES,	FI, GB, GD, GE, GH,
GM, HR, HU,	ID, IL, IN,	IS, JP, KE, KG, KP,	KR, KZ, LC, LK, LR,
LS, LT, LU,	LV, MA, MD, M	MG, MK, MN, MW, MX,	MZ, NI, NO, NZ, OM,

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2003264134 20040430 AU 2003-264134 20030829 Α1 PRIORITY APPLN. INFO.: DE 2002-10239832 A 20020829 WO 2003-EP9630 W 20030829

OTHER SOURCE(S):

MARPAT 140:236100

GI

AB Methods for the synthesis of title compds. [e.g., (I)], are claimed. Thus, tripeptide H-Pro-Phe-Phe(4-F)OEt [Phe(4-F) = L-4-fluorophenylalanine] was reacted with Boc-m-L-sarcolysin to give, after deprotection and work-up, I (34% yield, >90% purity). In in vivo toxicol. tests using DBA/2 mice, I had no toxicity deaths after 21 days at dosages of 8.0, 10.67, or 16.0 mg/kg (Melphalan reference, 1 dead at day 9 at 16.0 dosage). No data was presented for anti-tumor effectiveness of title compds.

IT 666829-49-8P 666829-50-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses) (preparation of sarcolysin oligopeptide derivs. for use in the treatment of

cancer)
RN 666829-49-8 CAPLUS

CN L-Phenylalanine, 3-[bis(2-chloroethyl)amino]-N-[[1-phenyl-5-(3-thienyl)-1H-pyrazol-3-yl]carbonyl]-L-phenylalanyl-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L-Phenylalanine, 3-[bis(2-chloroethyl)amino]-N-[[1-phenyl-5-(3-thienyl)-1Hpyrazol-3-yl]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2003:903255 CAPLUS

DOCUMENT NUMBER:

139:396168

TITLE:

Preparation of 3-pyridylpyrazole peptide derivatives

as prenylation inhibitors

INVENTOR(S):

Brown, Bradley B.; Rehder, Kenneth S.

PATENT ASSIGNEE(S):

SOURCE:

PPD Discovery, Inc., USA
U.S., 17 pp., Cont.-in-part of U.S. Ser. No. 219,628,

abandoned.

CODEN: USXXAM

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

	TENT										ICAT					ATE	
US	6649	638			В1		2003	1118	1	US 2	003-	3362	85		20		
WO	2004	0165	92		A1		2004	0226	1	WO 2	003-	US24:	985		20	0030	306
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	ΝZ,	OM,
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	TJ,	TM,	TN,
		TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	zw			
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	ΚZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NΕ,	SN,	TD,	TG
	2003																
US	2004	1164	25		A1		2004	0617	1	US 2	003-	6363	27		20	0030	306
	7166																
EP	1534	680			A1		2005	0601		EP 2	003-	7883	71		20	0030	306
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	ΑL,	TR,	BG,	CZ,	EE,	HU,	SK	
US	2004	0539	70		A1		2004	0318	1	US 2	003-	6462	56		20	00308	322
	6960						2005	1101									
US	2006	0254	54		A1		2006	0202	1	US 2	005-	2371	34		20	0050	927
	7112				B2		2006										
	2007															060,	714
US	2007	1495	49		A1		2007	0628	1	ÙS 2	007-	6189	32		20	0070	101
PRIORIT	Y APP	LN.	INFO	. :					1	US 2	002~	2196:	28	I	32 20	00208	314
											003-				A 20		
									1	US 2	003-	4545	54 P]	2 (0030	314
									1	US 2	003-	6363	27	7	A3 20	00308	306

WO 2003-US24985 W 20030806 US 2003-646256 A3 20030822 US 2005-237134 A3 20050927

GI

$$\begin{array}{c|c}
R^1 & O & R^2 \\
N & N & N & R^3 \\
\hline
N & O & R^3
\end{array}$$

The invention is directed to pyridylpyrazole compds. I [X is nitrogen, Ph, AΒ pyrazole, methylpyrazole, dimethylpyrazole, pyridine, thiophene, dimethylcyclobutyl, dimethylcyclopropyl or cyclopropyl; R1 is halophenyl; R2 is benzyl, iso-Pr, chlorobenzyl, methylthienyl, (trifluoromethyl)benzyl, ethylthiomethyl, or 1-benzyl-4-pyrazolylmethyl; R3 is NH2 or OH] for use in the treatment of diseases associated with prenylation of proteins. Thus, phenylalaninamide derivative II was prepared via

peptide coupling reactions and shown to inhibit GGPTase I.

I

IT 627088-86-2P

> RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridylpyrazole peptide derivs. as prenylation inhibitors) RN 627088-86-2 CAPLUS

CN Cyclohexanecarboxylic acid, [[[1-(3,4-dichlorophenyl)-5-(3-pyridinyl)-1Hpyrazol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



 $D1-CO_2H$

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 19

1992:612965 CAPLUS

DOCUMENT NUMBER:

117:212965

TITLE:

Preparation of N-(pyrazolylcarbonyl)amino acids and

analogs as antipsychotics

INVENTOR(S):

Boigegrain, Danielle; Gully, Robert; Jeanjean,

Francis; Molimard, Jean Charles

PATENT ASSIGNEE(S):

SOURCE:

Sanofi SA, Fr. Fr. Demande, 53 pp.

CODEN: FRXXBL

DOCUMENT TYPE:

Patent

LANGUAGE:

French

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2665898	A1	19920221	FR 1990-10486	19900820
FR 2665898 .	B1	19940311		
HU 59106	A2	19920428	HU 1991-2750	19910817
HU 217435	В	20000128		
FI 9103917	Α	19920221	FI 1991-3917	19910819
FI 104170	В	19991130		
FI 104170	B1	19991130		
NO 9103234	A	19920221	NO 1991-3234	19910819
NO 300212	B1	19970428		
BR 9103550	Α	19920407	BR 1991-3550	19910819
IL 99225	Α	19951031	IL 1991-99225	19910819
PL 169085	B1	19960531	PL 1991-291463	19910819
RU 2066317	C1	19960910	RU 1991-5001452	19910819
CA 2049514	A1	19920221	CA 1991-2049514	19910820
CA 2049514	С	19970225		
AU 9182596	A	19920227	AU 1991-82596	19910820
AU 646683	B2	19940303		
EP 477049	A1	19920325	EP 1991-402269	19910820
EP 477049	B1	19991201		

ZA 9106583 A 19920527 ZA 1991-6583 19	910820
JP 04244065 A 19920901 JP 1991-208108 19	910820
CZ 281864 B6 19970312 CZ 1991-2574 19	910820
CA 2166903 C 19980901 CA 1991-2166903 19	910820
CA 2166902 C 19990119 CA 1991-2166902 19	9910820
CA 2166901 C 19990126 CA 1991-2166901 19	9910820
KR 223074 B1 19991015 KR 1991-14358 19	9910820
AT 187167 T 19991215 AT 1991-402269 19	9910820
ES 2142798 T3 20000501 ES 1991-402269 19	9910820
LV 10434 B 19951020 LV 1993-138 19	9930225
LT 3520 B 19951127 LT 1993-656 19	9930615
US 5420141 A 19950530 US 1993-119830 19	9930913
US 5635526 A 19970603 US 1995-393829 19	9950224
US 5607958 A 19970304 , US 1995-394757 19	950227
US 5616592 A 19970401 US 1995-394756 19	950227
US 5744493 A 19980428 US 1996-775150 19	9961231
US 5744491 A 19980428 US 1997-778105 19	9970102
HK 1005136 A1 20000922 HK 1998-104340 19	9980519
GR 3032732 T3 20000630 GR 2000-400431 20	000223
PRIORITY APPLN. INFO.: FR 1990-10486 A 19	9900820
CA 1991-2049514 A3 19	9910820
US 1991-747359 B1 19	910820
	9930913
US 1995-393829 A3 19	9950224
US 1995-394756 A3 19	950227

OTHER SOURCE(S):

PhN-N

MARPAT 117:212965

GI

$$Q^{1} = \begin{array}{c} R^{5} & R^{4} \\ R^{1}N & Q^{2} = \\ N & R^{2} \end{array}$$

$$CONHCHCH_{2}CHMe_{2}$$

CO₂Me

AB R3CONR(CH2)nCXX1COZ [R = H, alkyl; R3 = pyrazolyl group Q1 or Q2; R1 = (substituted) Ph, carboxyalkyl, alkoxycarbonylalkyl, pyridyl, etc.; R2 = (substituted) PhCH2; R4 = H, halo, alkyl; R5 = alkyl, (substituted) Ph, naphthyl, pyridyl, etc.; R4R5 = atoms to complete a benznellated ring; X = H, alkyl; X1 = H, (substituted) alkyl, (hetero)aralkyl, etc.; when n = 0, RX1 = (hydroxy substituted) (CH2)4-6; CXX1 = cycloalkylidene; Z = OH, NH2, alkoxy, etc.; n = 0-3] were prepared as neurotensin receptor ligands (no data). Thus, R3CO2H (R3 = Q1; R1 = Ph, R4 = H, R5 = 4-pyridyl) was condensed with L-leucine Me ester in the presence of Et3N and R6OP(NMe2)3PF6 (R6 = benzotriazol-1-yl) to give title compound I.

IT 144250-74-8P 144251-34-3P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antipsychotic)

Ι

RN 144250-74-8 CAPLUS

CN L-Leucine, N-[[1-phenyl-5-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME) Absolute stereochemistry.

RN 144251-34-3 CAPLUS

CN L-Leucine, N-[[1-phenyl-5-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:103915 CAPLUS

DOCUMENT NUMBER: 90:103915

ORIGINAL REFERENCE NO.: 90:16415a,16418a

TITLE: Studies of unsaturated lactones. XXXV. Synthesis and

properties of 5-butenolidylpyrazole-3-carboxylic acid

esters

AUTHOR(S): Avetisyan, A. A.; Dzhandzhapanyan, A. N.; Dangyan, M.

Т.

CORPORATE SOURCE: Erevan. Gos. Univ., Yerevan, USSR

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1978), (12),

1611-14

CODEN: KGSSAQ; ISSN: 0453-8234

DOCUMENT TYPE: Journal

LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 90:103915

GI

The title compds. I [R = Me, Et, R2 = Ph, H, or RR1 = (CH2)5; R3 = OEt] were prepared in 62-77% yields by condensation of II (R4 = H) with (CO2Et)2 to give 80-97% II (R4 = COCO2Et) which were cyclized by heating with R2NHNH2 in AcOH. Amides I [R = R1 = Me, R2 = H, Ph, R3 = NHR5 (R5 = H, Bu, PhCH2)] were prepared in 41-80% yield by treatment of the esters I with R5NH2.

IT 66078-63-5P 69398-43-2P

RN 66078-63-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(2,5-dihydro-4,5,5-trimethyl-2-oxo-3-furanyl)-1-phenyl-N-(phenylmethyl)- (CA INDEX NAME)

RN 69398-43-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-butyl-5-(2,5-dihydro-4,5,5-trimethyl-2-oxo-3-furanyl)-1-phenyl- (CA INDEX NAME)

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:136514 CAPLUS

DOCUMENT NUMBER:

88:136514

ORIGINAL REFERENCE NO.:

88:21459a,21462a

TITLE:

Synthesis of some pyrazole derivatives containing an

unsaturated y-lactone ring

AUTHOR(S):

Dzhandzhapanyan, A. N.; Avetisyan, A. A.; Dangyan, M.

Т.

CORPORATE SOURCE:

Erevan. Gos. Univ., Yerevan, USSR

SOURCE:

Tezisy Dokl. - Molodezhnaya Konf. Org. Sint. Bioorg. Khim. (1976), 7-8. Akad. Nauk Arm. SSR, Inst. Tonkoi

Org. Khim. im. A. L. Mndzhoyana: Yerevan, USSR.

10/584,632

DOCUMENT TYPE:

CODEN: 37NNAQ Conference

LANGUAGE: Russian

GΙ

Pyrazolecarboxylates I (R = H, Ph, R1 = EtO) were prepared by AΒ cyclocondensation of RNHNH2 with II. Treatment of I with NH3 and PhCH2NH2 gave I [R = H, Ph, R1 NHR2 (R2 = H, PhCH2)].

IT 66078-63-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

66078-63-5 CAPLUS RN

1H-Pyrazole-3-carboxamide, 5-(2,5-dihydro-4,5,5-trimethyl-2-oxo-3-furanyl)-CN1-phenyl-N-(phenylmethyl) - (CA INDEX NAME)

=> d his

(FILE 'HOME' ENTERED AT 08:29:45 ON 31 JAN 2008)

FILE 'REGISTRY' ENTERED AT 08:29:56 ON 31 JAN 2008

STRUCTURE UPLOADED . L1

L2 6 S L1

L3 96 S L1 FULL

FILE 'CAPLUS' ENTERED AT 08:30:24 ON 31 JAN 2008

L411 S L3

=> d l1

L1 HAS NO ANSWERS

L1 STR

G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

= >